Prelude Therapeutics logo

Prelude Therapeutics Share Price Today

(NASDAQ: PRLD)

Prelude Therapeutics share price is $1.11 & ₹96.68 as on 5 Feb 2025, 2.30 'hrs' IST

$1.11

Market is closed - opens 8 PM, 05 Feb 2025

View live Prelude Therapeutics share price in Dollar and Rupees. Guide to invest in Prelude Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Prelude Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Prelude Therapeutics share price movements

  • Today's Low: $1.09
    Today's High: $1.14

    Day's Volatility :4.13%

  • 52 Weeks Low: $0.80
    52 Weeks High: $6.80

    52 Weeks Volatility :88.29%

Prelude Therapeutics (PRLD) Returns

PeriodPrelude Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-15.91%
0.5%
0.0%
6 Months
-78.24%
-2.3%
0.0%
1 Year
-61.99%
3.8%
0.0%
3 Years
-89.0%
11.4%
-11.7%

Prelude Therapeutics (PRLD) Key Statistics

in dollars & INR

Previous Close
$1.11
Open
$1.11
Today's High
$1.137
Today's Low
$1.09
Market Capitalization
$60.5M
Today's Volume
$64.6K
52 Week High
$6.8
52 Week Low
$0.7966
Revenue TTM
$3.0M
EBITDA
$-141.6M
Earnings Per Share (EPS)
$-1.77
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-66.64%

How to invest in Prelude Therapeutics Stock (PRLD) from India?

It is very easy for Indian residents to invest directly in Prelude Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Prelude Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Prelude Therapeutics or PRLD on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Prelude Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Prelude Therapeutics shares which would translate to 0.785 fractional shares of Prelude Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Prelude Therapeutics, in just a few clicks!

Returns in Prelude Therapeutics (PRLD) for Indian investors in Rupees

The Prelude Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Prelude Therapeutics investment value today

Current value as on today

₹42,878

Returns

₹57,122

(-57.12%)

Returns from Prelude Therapeutics Stock

₹61,986 (-61.99%)

Dollar Returns

₹4,865 (+4.86%)

Indian investors sentiment towards Prelude Therapeutics (PRLD)

-33%

Period: Jan 5, 2025 to Feb 4, 2025. Change in 30 Days versus previous period

Search interest for Prelude Therapeutics Stock from India on INDmoney has decreased by -33% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Prelude Therapeutics

  • Orbimed Advisors, LLC

    19.82%

  • Baker Bros Advisors LP

    18.40%

  • Deerfield Management Co

    6.84%

  • Boxer Capital LLC

    3.10%

  • T. Rowe Price Associates, Inc.

    1.99%

  • BlackRock Inc

    1.92%

Analyst Recommendation on Prelude Therapeutics

Sell

    11%Buy

    44%Hold

    44%Sell

Based on 9 Wall street analysts offering stock ratings for Prelude Therapeutics(by analysts ranked 0 to 5 stars)

Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
1
Hold
4
4
3
Sell
4
4
4

Analyst Forecast on Prelude Therapeutics Stock (PRLD)

What analysts predicted

Upside of 350.45%

Target:

$5.00

Current:

$1.11

Insights on Prelude Therapeutics Stock (Ticker Symbol: PRLD)

  • Price Movement

    In the last 6 months, PRLD stock has moved down by -81.0%
  • PRLD vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 58.6% return, outperforming this stock by 122.2%
  • PRLD vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 88.8% return, outperforming this stock by 177.5%
  • Price to Sales

    ForPRLD every $1 of sales, investors are willing to pay $27.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.6 for every $1 of sales.

Prelude Therapeutics Technicals Summary

Sell

Neutral

Buy

Prelude Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Prelude Therapeutics (PRLD) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Prelude Therapeutics Inc logo
-16.54%
-78.24%
-61.99%
-89.0%
-95.76%
Biontech Se logo
-0.32%
51.19%
24.81%
-30.66%
288.02%
Regeneron Pharmaceuticals, Inc. logo
-6.9%
-37.55%
-28.89%
7.15%
74.63%
Vertex Pharmaceuticals Incorporated logo
16.87%
0.96%
13.03%
93.36%
95.94%
Alnylam Pharmaceuticals, Inc. logo
17.76%
5.53%
59.46%
84.7%
118.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Prelude Therapeutics Inc logo
NA
NA
NA
-1.77
-0.67
-0.39
NA
2.84
Biontech Se logo
160.8
NA
0.04
-3.32
-0.02
-0.01
NA
79.73
Regeneron Pharmaceuticals, Inc. logo
16.64
16.64
1.08
44.92
0.17
0.07
NA
272.04
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.21
0.49
-0.03
0.12
NA
60.65
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
-0.18
-15.01
-0.03
NA
0.25
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Prelude Therapeutics Inc logo
Sell
$60.5M
-95.76%
NA
0.0%
Biontech Se logo
Buy
$29.7B
288.02%
160.8
-15.36%
Regeneron Pharmaceuticals, Inc. logo
Buy
$74.0B
74.63%
16.64
33.61%
Vertex Pharmaceuticals Incorporated logo
Buy
$118.9B
95.94%
32.84
-4.51%
Alnylam Pharmaceuticals, Inc. logo
Buy
$35.0B
118.8%
NA
-15.86%

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Organization
Prelude Therapeutics
Employees
128
CEO
Dr. Krishna Vaddi D.V.M., Ph.D.
Industry
Health Technology

Management People of Prelude Therapeutics

NameTitle
Dr. Krishna Vaddi D.V.M., Ph.D.
Founder, CEO & Director
Dr. Edna Huang M.D.
President & Chief Medical Officer
Mr. Bryant David Lim J.D.
Interim CFO, Chief Legal Officer & Corporate Secretary
Ms. Aimee Crombie Ph.D.
Senior VP and Head of Strategic Planning & Operations
Dr. Madhu Pudipeddi Ph.D.
Senior Vice President of Technical Operations
Dr. Peggy A. Scherle Ph.D.
Chief Scientific Officer
Ms. Michele Porreca M.B.A.
Chief People Officer
Dr. Andrew P. Combs Ph.D.
Executive VP & Chief Chemistry Officer
Mr. Naveen Babbar Ph.D.
Senior Vice President of Translation Medicine
Dr. William B. Novotny M.D.
Senior Vice President of Clinical Development

Important FAQs about investing in PRLD Stock from India :

What is Prelude Therapeutics share price today?

Prelude Therapeutics share price today stands at $1.11, Open: $1.11 ; Previous Close: $1.11 ; High: $1.14 ; Low: $1.09 ; 52 Week High: $6.80 ; 52 Week Low: $0.80.

The stock opens at $1.11, after a previous close of $1.11. The stock reached a daily high of $1.14 and a low of $1.09, with a 52-week high of $6.80 and a 52-week low of $0.80.

Can Indians buy Prelude Therapeutics shares?

Yes, Indians can invest in the Prelude Therapeutics (PRLD) from India.

With INDmoney, you can buy Prelude Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Prelude Therapeutics at zero transaction cost.

How can I buy Prelude Therapeutics shares from India?

It is very easy to buy Prelude Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Prelude Therapeutics (PRLD) be purchased?

Yes, you can buy fractional shares of Prelude Therapeutics with INDmoney app.

What are the documents required to start investing in Prelude Therapeutics stocks?

To start investing in Prelude Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Prelude Therapeutics Stock (PRLD)?

Today’s highest price of Prelude Therapeutics (PRLD) is $1.14.

Today’s lowest price of Prelude Therapeutics (PRLD) is $1.09.

What is today's market capitalisation of Prelude Therapeutics?

Today's market capitalisation of Prelude Therapeutics PRLD is 60.5M

What is the 52 Week High and Low Range of Prelude Therapeutics Stock (PRLD)?

  • 52 Week High

    $6.80

  • 52 Week Low

    $0.80

What are the historical returns of Prelude Therapeutics (PRLD)?

  • 1 Month Returns

    -16.54%

  • 3 Months Returns

    -78.24%

  • 1 Year Returns

    -61.99%

  • 5 Years Returns

    -95.76%

Who is the Chief Executive Officer (CEO) of Prelude Therapeutics ?

Dr. Krishna Vaddi D.V.M., Ph.D. is the current Chief Executive Officer (CEO) of Prelude Therapeutics.